Clinical Trial Calendar

Results Date
Company Name
Q4 2021
Cortexyme Inc
Top-line data from Phase 2/3 clinical trial of COR388 (GAIN trial)
Mild to moderate Alzheimer's disease dementia
Q4 2021
Frequency therapeutics
Topline results from Phase 1b clinical trial of FX-322
Sensorineural hearing loss or SNHL
Q4 2021
Trevi Therapeutics
Topline data from phase IIb/III clinical trial of Nalbuphine ER (PRISM)
Severe pruritus associated with prurigo nodularis
Oct 2021
Phathom Pharmaceuticals Inc
Topline data from pivotal phase III clinical trial of Vonoprazan (PHALCON-EE)
Healing of erosive esophagitis (EE) as well as relief of heartburn
Q4 2021
Sierra Oncology, Inc.
Top-line data from phase III trial to confirm efficacy of Momelotinibl ( MOMENTUM)
Myelofibrosis symptoms, transfusion independence, and splenomegaly
Q4 2021
Topline results from phase 1b/2a clinical trial of NM-002
Short bowel syndrome
Q4 2021
NextCure Inc
Initial data from Phase 1 portion of Phase 1/2 trial of NC410
Solid Tumors
Q4 2021
Initial 30-day safety and biomarker data from Phase 1/2 trial of PBGM01
Infantile GM1 gangliosidosis
Oct 2021
Phathom Pharmaceuticals Inc
Topline data from phase 3 trial of Vonoprazan (PHALCON-EE)
Erosive esophagitis
Q4 2021
Calithera Biosciences Inc.
Interim data from randomized trial of telaglenastat With Standard-of-Care Chemoimmunotherapy(KEAPSAKE )
Non-small cell lung cancer (NSCLC) patients with a KEAP1 or NRF2 genetic mutation
Q4 2021
Daré Bioscience, Inc
Topline data from Phase 2b study of Sildenafil Cream (3.6%)
Female sexual arousal disorder
Q4 2021
Evelo Biosciences, Inc.
Data from Phase 1b trial of EDP1867
Atopic dermatitis
16-Sep-2021 To 21-Sep-2021
Ayala Pharmaceuticals, Inc.
Additional data from phase II trial of AL101( ACCURACY )
Recurrent/metastatic adenoid cystic carcinoma patients with Notch activating mutations
Cardiff Oncology, Inc.
New data from phase Ib/II trial of Onvansertib in combination with FOLFIRI/Avastin
second-line treatment of patients with KRAS-mutated metastatic colorectal cancer
Forte Biosciences, Inc.
Topline data from phase II clinical trial of FB-401
Atopic dermatitis
Pliant Therapeutics, Inc.
Interim clinical data from phase IIa positron emission tomography (PET) imaging trial of PLN-74809
Idiopathic pulmonary fibrosis
Mid Sep 2021
aTyr Pharma Inc.
Data from phase 1b/2a clinical trial of ATYR1923 i
Pulmonary sarcoidosis
Sep 2021
Gritstone bio, Inc.
Comprehensive data update from phase I/II GRANITE program
Metastatic microsatellite stable colorectal cancer (MSS-CRC), gastroesophageal (GEA) cancer and non-small cell lung cancer (NSCLC)
after Q4 2021
Inhibrx, Inc.
Initial data from phase I trial of INBRX-101
Alpha-1 Antitrypsin Deficiency in adults
after Q4 2021
Global Blood Therapeutics
Proof-of-concept data from phase I trial of GBT601
Sickle cell disease
after Q4 2021
Aurinia Pharmaceuticals Inc.
Top-line results from phase III continuation study of Lupkynis (AURORA 2)
Lupus nephritis
after Q4 2021
Nurix Therapeutics, Inc.
Initial pharmacokinetic (PK) and pharmacodynamic (PD) data from phase 1a trial of NX-2127
B-cell malignancies who have failed prior treatments
after Q4 2021
Nkarta, Inc.
Initial clinical data from phase I trial of NKX101
Relapsed/refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndromes
after Q4 2021
Celyad SA
Additional clinical data from phase 1 dose escalation trial of CYAD-211 (IMMUNICY-1)
Relapsed or Refractory Multiple Myeloma
after Q4 2021
Celyad SA
Additional data from dose-escalation Phase 1 trial of CYAD-02 (CYCLE-1 )
Relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (MDS)